Literature DB >> 32675077

Automated analysis of natural speech in amyotrophic lateral sclerosis spectrum disorders.

Naomi Nevler1, Sharon Ash2, Corey McMillan2, Lauren Elman2, Leo McCluskey2, David J Irwin2, Sunghye Cho2, Mark Liberman2, Murray Grossman1.   

Abstract

OBJECTIVE: We implemented automated methods to analyze speech and evaluate the hypothesis that cognitive and motor factors impair prosody in partially distinct ways in patients with amyotrophic lateral sclerosis (ALS).
METHODS: We recruited 213 participants, including 67 with ALS (44 with motor ALS, 23 with ALS and frontotemporal degeneration [FTD]), 33 healthy controls, and neurodegenerative reference groups with behavioral variant FTD (n = 90) and nonfluent/agrammatic primary progressive aphasia (n = 23). Digitized, semistructured speech samples obtained from picture descriptions were automatically segmented with a Speech Activity Detector; continuous speech segments were pitch-tracked; and duration measures for speech and silent pause segments were extracted. Acoustic measures were calculated, including fundamental frequency (f0) range, mean speech and pause segment durations, total speech duration, and pause rate (pause count per minute of speech). Group comparisons related performance on acoustic measures to clinical scales of cognitive and motor impairments and explored MRI cortical thinning in ALS and ALS-FTD.
RESULTS: The f0 range was significantly impaired in ALS spectrum disorders and was related to bulbar motor disease, and regression analyses related this to cortical thickness in primary motor cortex and perisylvian regions. Impaired speech and pause duration measures were related to the degree of cognitive impairment in ALS spectrum disorders, and regressions related duration measures to bilateral frontal opercula and left anterior insula.
CONCLUSION: Automated analyses of acoustic speech properties dissociate motor and cognitive components of speech deficits in ALS spectrum disorders.
© 2020 American Academy of Neurology.

Entities:  

Mesh:

Year:  2020        PMID: 32675077      PMCID: PMC7713725          DOI: 10.1212/WNL.0000000000010366

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  46 in total

1.  An open source multivariate framework for n-tissue segmentation with evaluation on public data.

Authors:  Brian B Avants; Nicholas J Tustison; Jue Wu; Philip A Cook; James C Gee
Journal:  Neuroinformatics       Date:  2011-12

2.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

Authors:  J M Cedarbaum; N Stambler; E Malta; C Fuller; D Hilt; B Thurmond; A Nakanishi
Journal:  J Neurol Sci       Date:  1999-10-31       Impact factor: 3.181

3.  Differentiating primary progressive aphasias in a brief sample of connected speech.

Authors:  Sharon Ash; Emily Evans; Jessica O'Shea; John Powers; Ashley Boller; Danielle Weinberg; Jenna Haley; Corey McMillan; David J Irwin; Katya Rascovsky; Murray Grossman
Journal:  Neurology       Date:  2013-06-21       Impact factor: 9.910

4.  Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes.

Authors:  Eneida Mioshi; Patricia Lillo; Belinda Yew; Sharpley Hsieh; Sharon Savage; John R Hodges; Matthew C Kiernan; Michael Hornberger
Journal:  Neurology       Date:  2013-02-20       Impact factor: 9.910

5.  Primary progressive aphasia and the FTD-MND spectrum disorders: clinical, pathological, and neuroimaging correlates.

Authors:  Giulia Vinceti; Nicholas Olney; Maria Luisa Mandelli; Salvatore Spina; H Isabel Hubbard; Miguel A Santos-Santos; Christa Watson; Zachary A Miller; Catherine Lomen-Hoerth; Paolo Nichelli; Bruce L Miller; Lea T Grinberg; William W Seeley; Maria Luisa Gorno-Tempini
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2019-01-22       Impact factor: 4.092

6.  Multi-Atlas Segmentation with Joint Label Fusion.

Authors:  Hongzhi Wang; Jung W Suh; Sandhitsu R Das; John B Pluta; Caryne Craige; Paul A Yushkevich
Journal:  IEEE Trans Pattern Anal Mach Intell       Date:  2012-06-26       Impact factor: 6.226

7.  Linear associations between clinically assessed upper motor neuron disease and diffusion tensor imaging metrics in amyotrophic lateral sclerosis.

Authors:  John H Woo; Sumei Wang; Elias R Melhem; James C Gee; Andrew Cucchiara; Leo McCluskey; Lauren Elman
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

8.  Right Hemisphere Regions Critical for Expression of Emotion Through Prosody.

Authors:  Sona Patel; Kenichi Oishi; Amy Wright; Harry Sutherland-Foggio; Sadhvi Saxena; Shannon M Sheppard; Argye E Hillis
Journal:  Front Neurol       Date:  2018-04-06       Impact factor: 4.003

9.  Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis?

Authors:  Lorna J Taylor; Richard G Brown; Stella Tsermentseli; Ammar Al-Chalabi; Christopher E Shaw; Catherine M Ellis; P Nigel Leigh; Laura H Goldstein
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-10-02       Impact factor: 10.154

10.  101 labeled brain images and a consistent human cortical labeling protocol.

Authors:  Arno Klein; Jason Tourville
Journal:  Front Neurosci       Date:  2012-12-05       Impact factor: 4.677

View more
  2 in total

1.  Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches.

Authors:  Corey T McMillan; Joanne Wuu; Katya Rascovsky; Stephanie Cosentino; Murray Grossman; Lauren Elman; Colin Quinn; Luis Rosario; Jessica H Stark; Volkan Granit; Hannah Briemberg; Sneha Chenji; Annie Dionne; Angela Genge; Wendy Johnston; Lawrence Korngut; Christen Shoesmith; Lorne Zinman; Sanjay Kalra; Michael Benatar
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2022-03-07       Impact factor: 3.528

Review 2.  Cognitive and Behavioral Manifestations in ALS: Beyond Motor System Involvement.

Authors:  Robert Rusina; Rik Vandenberghe; Rose Bruffaerts
Journal:  Diagnostics (Basel)       Date:  2021-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.